Company type | Public limited company |
---|---|
ISIN | GB00BMX86B70 |
Industry | |
Predecessors | |
Founded | 18 July 2022 |
Headquarters | Weybridge, Surrey, England |
Area served | Worldwide |
Key people |
|
Products |
|
Brands | |
Revenue | £11,302 million (2023) [1] |
£1,996 million (2023) [1] | |
£1,111 million (2023) [1] | |
Total assets | £34,055 million (2023) [1] |
Total equity | £16,729 million (2023) [1] |
Number of employees | 24,000 (2023) [2] |
Website |
www |
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. [3] It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins. [4] The company is a global leader in over the counter medicines with a 7.3 percent market share. [5]
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6]
Sir David Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020. [5]
GSK and Pfizer merged their consumer healthcare businesses in 2019. [8] [9] GSK owned just over two thirds of the joint venture, and Pfizer held the remainder. [8]
GSK announced plans to spin-off Haleon in 2018, in order to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division". [10]
Unilever offered £50 billion for the business in 2022, in a bid which GSK rejected. [11] Nestlé examined the possibility of a bid in conjunction with Reckitt. [12]
In October 2023, GSK reduced its ownership share in Haleon to just over 7.4%, [13] and again in January 2024 down to 4.2%. [14]
The ChapStick lip care brand was sold to Yellow Wood Partners for £401 million in 2024. [15]
In March 2024, Pfizer reduced its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering. [16]
Oral health accounted for 28.5 percent of revenue in 2021. [17]
Brands include: [18]
Company type | Public limited company |
---|---|
ISIN | GB00BMX86B70 |
Industry | |
Predecessors | |
Founded | 18 July 2022 |
Headquarters | Weybridge, Surrey, England |
Area served | Worldwide |
Key people |
|
Products |
|
Brands | |
Revenue | £11,302 million (2023) [1] |
£1,996 million (2023) [1] | |
£1,111 million (2023) [1] | |
Total assets | £34,055 million (2023) [1] |
Total equity | £16,729 million (2023) [1] |
Number of employees | 24,000 (2023) [2] |
Website |
www |
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. [3] It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins. [4] The company is a global leader in over the counter medicines with a 7.3 percent market share. [5]
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6]
Sir David Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020. [5]
GSK and Pfizer merged their consumer healthcare businesses in 2019. [8] [9] GSK owned just over two thirds of the joint venture, and Pfizer held the remainder. [8]
GSK announced plans to spin-off Haleon in 2018, in order to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division". [10]
Unilever offered £50 billion for the business in 2022, in a bid which GSK rejected. [11] Nestlé examined the possibility of a bid in conjunction with Reckitt. [12]
In October 2023, GSK reduced its ownership share in Haleon to just over 7.4%, [13] and again in January 2024 down to 4.2%. [14]
The ChapStick lip care brand was sold to Yellow Wood Partners for £401 million in 2024. [15]
In March 2024, Pfizer reduced its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering. [16]
Oral health accounted for 28.5 percent of revenue in 2021. [17]
Brands include: [18]